A phase 1/2 trial of Verteporfin in prostate cancer, run by SpectraCure AB, now recruiting.
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System is a phase 1/2 interventional study registered as NCT03067051 by SpectraCure AB, with 66 participants planned, started 2017-03-21 and due to reach its primary completion in 2027-07-31. Interventions recorded: Verteporfin and SpectraCure P18 System.
Shares SpectraCure, Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.